Structuring analytical data for the future of regulatory submission with INDiGO

Bringing a small molecule from candidate nomination to clinical development is often a fragmented process, with handoffs between teams creating delays, increasing costs, and introducing risk. At the same time, up to 90% of drug candidates fail before market approval, highlighting the need for smarter strategies to identify and address potential roadblocks as early as possible.

This resource explores how Evotec’s INDiGO^® and INDiGO-Select platforms streamline development through an integrated, science-driven approach. Discover how INDiGO-Select reduces IND-enabling attrition from 30–40% to 5%, and learn how early de-risking can accelerate timelines, strengthen confidence, and improve the chances of clinical success.